Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver high quality critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization.

Thomson Reuters can provide the knowledge, tools and expertise to help support your drug discovery and development activities, optimize your IP portfolio, identify licensing and partnering opportunities, deliver successful regulatory submissions, keep you in touch with the rapidly-changing pharmaceutical and chemical markets, and make informed, early decisions.
 

BioPharm Insight is the leading provider of intelligence to the biotechnology & pharmaceutical industry. We provide: detailed company profiles for over 4,400 biotech & pharmaceutical companies; listings on 36,000+ investigational & 23,000+ approved drugs; contact info for 250,000+ industry contacts (includes email & direct phone); 3,000+, easy-to-digest, licensing agreement synopses; product forecasts through 2018; and exclusive editorial intelligence. Our proprietary journalists cover the most important situations taking place in the life sciences industry. They tap leading CEOs, scientists, clinicians, lawyers, and other experts to provide forward looking insight into drug pipelines, upcoming litigation (including patent expirations), drug licensing deals, and mergers & acquisitions.